ENTITY
Everest Medicines

Everest Medicines (1952 HK)

138
Analysis
Health Care • China
Everest Medicines Limited operates as a late clinical-stage biopharmaceutical company. The Company engages in licensing, clinical development, and commercialization of therapies for oncology, immunology, cardio-renal disease, and infectious disease. Everest Medicines markets its products in China and other emerging Asia Pacific markets.
more
•11 Oct 2020 13:42

ECM Weekly (11 October 2020) - Excellence Comm, MR DIY, Converge ICT, Simcere, SciClone, JW Thera

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming...

Share
•11 Oct 2020 09:34

A Different Angle -Ā Simcere Pharmaceutical VS Everest Medicines (01952.HK)

Everest Medicines was listed in Hong Kong stock market on October 9, 2020 and closed at HK$72.75 (up 32.27% on the first day) . From the...

Logo
507 Views
Share
bullish•Everest Medicines
•08 Oct 2020 12:36

Everest Medicines (云锶新耀) IPO: A Hot Deal Lacks Valuation Support

Everest raised HKD 3,281 million (USD 423\m) from its global offering and will list on the Hong Kong Stock Exchange tomorrow.

Logo
665 Views
Share
•04 Oct 2020 12:46

ECM Weekly (4 October 2020) - JD Health, MINISO, Everest Med, Weihai Comm Bank, JD Digits

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming...

Share
bullish•Everest Medicines
•28 Sep 2020 20:07

Everest Medicines IPO: Valuation Insights

Ocumension Therapeutics (1477 HK)Ā is a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing...

Logo
737 Views
Share
x